Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

NCT02733445 · clinicaltrials.gov ↗

COMPLETED

Status

2650

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia (CML)

Interventions

DRUG: dasatinib
DRUG: nilotinib

Sponsor

Bristol-Myers Squibb